APA (7th ed.) Citation

Agarwal, N., Vaishampayan, U., Green, M., Nucci, F. d., Chang, P., Scheffold, C., & Pal, S. (2018). 872PPhase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: Results of the dose escalation stage in patients (pts) with treatment-naïve advanced renal cell carcinoma (RCC). Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy283.081

Chicago Style (17th ed.) Citation

Agarwal, N., U. Vaishampayan, M. Green, F di Nucci, P-Y Chang, C. Scheffold, and S. Pal. "872PPhase Ib Study (COSMIC-021) of Cabozantinib in Combination with Atezolizumab: Results of the Dose Escalation Stage in Patients (pts) with Treatment-naïve Advanced Renal Cell Carcinoma (RCC)." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy283.081.

MLA (9th ed.) Citation

Agarwal, N., et al. "872PPhase Ib Study (COSMIC-021) of Cabozantinib in Combination with Atezolizumab: Results of the Dose Escalation Stage in Patients (pts) with Treatment-naïve Advanced Renal Cell Carcinoma (RCC)." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy283.081.